We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.002 | 0.13% | 1.567 | 1.536 | 1.598 | 1.55 | 1.538 | 1.55 | 4,833,427 | 16:35:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.40 | 17.59M |
Date | Subject | Author | Discuss |
---|---|---|---|
27/2/2024 12:02 | Now the other thing that as actual shareholders we all know is that at some stage further funding will be required to get through to phases 2 & 3 We just don't know when and how? One possibility is that potentially a major industry player could offer funding as part of a long term collaboration? But for now all guess work and that is the 100% honest approach! | apotheki | |
27/2/2024 12:01 | Amongst various posts on this HEMO thread including posts 806 & 807 in the very recent past notably September & November 2023 a total of circa £1.25m was raised to add to the existing coffers. One of those two fund raising was at a substantial premium which could potentially of course be replicated at some point! So whilst they might raise again soon they might not! And if they do it could once again be at a substantial premium! None of us know for sure and that includes the TROLL but the above is for balance as well as being based on actual FACTS! | apotheki | |
27/2/2024 11:54 | Prove all of those [what you describe as] FACTS [in other words put up or shut up] P.S. - we all know that you are just another nickname for that other TROLL starting with d.... | apotheki | |
27/2/2024 11:51 | Thanks Log. | premium beeks | |
27/2/2024 11:50 | They are skint FACT! They need to raise FACT! They struggled to raise anything significant last time FACT! There's been no proper institutional interest FACT! There are many many similar firms doing what they do and HEMO seems to be practically unknown in that space FACT! | loglorry1 | |
27/2/2024 11:32 | Does it?It may well do, however it could equally be they are undertaking commercially sensitive negotiations and we are in a no news lull. The price isn't dropping in a way that suggests the company is doing the City rounds for funding, it's low volume drip as people move on for more exciting things.You can spin your negative slant how you want, I"ll continue to be objective until firm facts are known. | premium beeks | |
27/2/2024 11:24 | Yes because they are struggling to raise and the share price tells you that. | loglorry1 | |
27/2/2024 11:19 | It was below 3p last week and now below 2p.I await the next guess on absolute hot air. | premium beeks | |
27/2/2024 11:13 | They are running on empty and in the last raise only managed enough to keep the lights on for a couple of months. They have FDA green light for Phase 1 but no money to fund it. No serious institutions on the share register and like many other biotech companies out there they seem to be struggling to raise. I think they'll raise money below 2p fwiw and they need to do so quite quickly. | loglorry1 | |
27/2/2024 10:32 | Findings Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells. The journal Blood published the preclinical findings today. By overcoming challenges, such as drug resistance and treatment relapse common to patients with acute myeloid leukemia (AML), the therapy method could provide a less toxic and more effective approach for older and sicker patients who don't quality for stem cell transplants Sadly the Hemogenyx CDX platform remains in the Petri Dish, The technology that raised countless millions in subscriptions from investors to be replaced by the Cd19flt33 Car-T platform which requires Further First aid from the investors wallets🍒 | dreamtwister | |
27/2/2024 10:32 | Exactly right.It's all guesswork until the company tells us. The silence is deafening at the moment, I'd expect there's a lot of discussions behind closed doors as to what comes next.Meanwhile the price is likely to drift in the interim. Just a fact of life in such a situation. | premium beeks | |
27/2/2024 10:26 | Now the other thing that as actual shareholders we all know is that at some stage further funding will be required to get through to phases 2 & 3 We just don't know when and how? One possibility is that potentially a major industry player could offer funding as part of a long term collaboration? But for now all guess work and that is the 100% honest approach! | apotheki | |
27/2/2024 10:23 | Amongst various posts on this HEMO thread including posts 806 & 807 in the very recent past notably September & November 2023 a total of circa £1.25m was raised to add to the existing coffers. One of those two fund raising was at a substantial premium which could potentially of course be replicated at some point! So whilst they might raise again soon they might not! And if they do it could once again be at a substantial premium! None of us know for sure and that includes the TROLL but the above is for balance as well as being based on actual FACTS! | apotheki | |
27/2/2024 10:17 | dreamtwister27 Feb '24 - 09:00 - 861 of 862 (Filtered) dreamtwister27 Feb '24 - 09:17 - 862 of 862 (Filtered) dreamtwister27 Feb '24 - 09:48 - 864 of 864 (Filtered) | apotheki | |
27/2/2024 09:40 | dreamtwister27 Feb '24 - 09:00 - 861 of 862 (Filtered) dreamtwister27 Feb '24 - 09:17 - 862 of 862 (Filtered) | apotheki | |
27/2/2024 09:17 | So whilst the Hemogenyx Science remains in Regression ! The science Evolves ! the link above " yes open it & read it " Behind the Scenes the science is becoming Assessable...Afforda Risk Adverse "contamination" patient Safety & Age related. So Dr Sandler Has the Greenlight for the commencement of the clinical trials to Enroll the patients that has their body clock ticking bye ? | dreamtwister | |
26/2/2024 19:29 | I bet your mum is still in a state of confusion wondering why she didn't swallow.Imagine being so dense that you keep repeating the obvious thinking you have a found a top secret fact. Keep going. If it keeps you busy it's probably good for society overall. | justaman | |
26/2/2024 11:49 | well the above statement by Justaman is in a state of confusion ! The company statement has spelt it out in laymans terms: the cash burn is incinerating our working Capital ! The company Statement.! “Substantial funding will be required by the Company during the clinical trial phase and further funding will be sought by the Company prior to the commencement of the Phase I clinical trials.🍒 lets wait & see the eoy report !...can post in Brail if you like. | dreamtwister | |
26/2/2024 10:33 | dreamtwister26 Feb '24 - 10:02 - 855 of 855 (Clueless C0ck) | premium beeks | |
26/2/2024 10:30 | dreamtwister26 Feb '24 - 10:02 - 855 of 855 (Filtered) | apotheki | |
26/2/2024 10:02 | justaman... vlad has got to sell the science before going forward ! over the last decade the Major industry pharmaceuticals have taken up their collaborations ,Though as the new financel year dawns they may take a vested interest after running the slide rule over the Hemogenyx books no doubt the v/capitalist mind set will follow ,so will that entail the Pi to take Dr Sandlers Awarded share Options The Blessing would be for you to study the WWW.INVESTINGFORDUMM end of year results reveal. Here is a clue "hence not my Words ! A company Statement.! “Substantial funding will be required by the Company during the clinical trial phase and further funding will be sought by the Company prior to the commencement of the Phase I clinical trials. | dreamtwister |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions